- Home
- EQ vs VHC Comparison
EQ vs VHC Comparison
Compare EQ & VHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- VHC
- Stock Information
- Founded
- EQ 2017
- VHC 2005
- Country
- EQ United States
- VHC United States
- Employees
- EQ N/A
- VHC N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- VHC Multi-Sector Companies
- Sector
- EQ Health Care
- VHC Miscellaneous
- Exchange
- EQ Nasdaq
- VHC Nasdaq
- Market Cap
- EQ 24.8M
- VHC 26.2M
- IPO Year
- EQ 2018
- VHC 1999
- Fundamental
- Price
- EQ $0.63
- VHC $8.89
- Analyst Decision
- EQ Buy
- VHC
- Analyst Count
- EQ 2
- VHC 0
- Target Price
- EQ $5.00
- VHC N/A
- AVG Volume (30 Days)
- EQ 130.9K
- VHC 48.3K
- Earning Date
- EQ 11-13-2024
- VHC 03-14-2025
- Dividend Yield
- EQ N/A
- VHC N/A
- EPS Growth
- EQ N/A
- VHC N/A
- EPS
- EQ N/A
- VHC N/A
- Revenue
- EQ $45,914,000.00
- VHC $5,000.00
- Revenue This Year
- EQ $4.76
- VHC N/A
- Revenue Next Year
- EQ N/A
- VHC N/A
- P/E Ratio
- EQ N/A
- VHC N/A
- Revenue Growth
- EQ 7.70
- VHC N/A
- 52 Week Low
- EQ $0.49
- VHC $3.55
- 52 Week High
- EQ $3.25
- VHC $9.69
- Technical
- Relative Strength Index (RSI)
- EQ 37.33
- VHC 67.42
- Support Level
- EQ $0.49
- VHC $6.76
- Resistance Level
- EQ $0.73
- VHC $9.69
- Average True Range (ATR)
- EQ 0.08
- VHC 0.74
- MACD
- EQ -0.01
- VHC 0.20
- Stochastic Oscillator
- EQ 38.92
- VHC 74.52
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About VHC VirnetX Holding Corp
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services, and critical infrastructures.